For now I'm just staying the course with Arena, Vivus did not get positive feedback from the FDA panel so that leaves two companies vying for a $10 Billion market right now, the other looks to have the same issues Vivus has. 20% of the market easily valuates ARNA @ $20 per share, that is a lowball price.